💊 Get Accurate, Objective, and Timely Intelligence From DrugPatentWatch
Profile for Enanta Pharmaceuticals, Inc. (ENTA)
« Back to company indexENTA Chatter Timeline
Stock Ticker for ENTA
Most Active Tweeters for ENTA
| User | Tweets |
|---|---|
| @insidertra | 6 |
| @FintelAlerts | 4 |
| @otcdynamics | 3 |
| @day_trading_de | 3 |
| @Tickeron | 3 |
Recent Tweets for ENTA
 |
@fda_tracker $ENTA Phase 2 trial w/est Mar completion date NCT05616728: https://t.co/c9YEhMGw74 Trial Tracker: https://t.co/aR7q5osthn March 21st 2023, 1:03pm |
 |
@gtrades31 $ENTA Blocktrade Sale of $1.22M SHARES 29.35K ? Filled at Bid @ 41.73 #Blocktrades March 20th 2023, 9:03pm |
 |
@mediasentiment $ENTA new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 185 March 20th 2023, 9:03am |
|
@mediasentiment $ENTA new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 184 March 20th 2023, 9:03am |
 |
@PaulTorresCohen Paul Torres-Cohen $ENTA March 20th 2023, 1:03am |
 |
@Tickeron $ENTA's 10-day Moving Average broke below its 50-day Moving Average on February 28, 2023. View odds for this and ot… https://t.co/rOPy1SzFX6 March 19th 2023, 4:03pm |
|
@Tickeron How will this affect the market? $ENTA price may climb as it broke lower Bollinger Band. #EnantaPharmaceuticals… https://t.co/ixLFXG1Bhd March 18th 2023, 10:03pm |
 |
@FlashAlert_me $ENTA [15s. delayed] filed SEC form 4: Director Vance Terry: Converted securities 5,800 of Common Stock at price $… https://t.co/vFWYL5OYB0 March 17th 2023, 10:03pm |
 |
@day_trading_de ENTA (ENANTA PHARMACEUTICALS INC) ? #Insider #stock alert! ? #Sale on 2023-03-15 - $ENTA ??: MELLETT PAUL J (Treasu… https://t.co/c0gsH39H6h March 17th 2023, 10:03pm |
 |
@FintelAlerts Insider Paul J Mellett reports selling 10,440 shares of $ENTA for a total cost of $463,802.20 https://t.co/dsWcxcyh2v March 17th 2023, 10:03pm |
|
@FlashAlert_me $ENTA [15s. delayed] filed SEC form 4: Treasurer and CFO MELLETT PAUL J: Disposed 10,440 of Common Stock at averag… https://t.co/Qy5Eqe6CMc March 17th 2023, 10:03pm |
 |
@insidertra $ENTA ENANTA PHARMACEUTICALS INC, MELLETT PAUL J, purchased shares valued at 146160 USD, date 2023-03-15, posted 2023-03-17T18:41:12 ? March 17th 2023, 10:03pm |
|
@insidertra $ENTA, ENANTA PHARMACEUTICALS INC, MELLETT PAUL J, sold shares valued at 463802 USD, date 2023-03-15, posted 2023-03-17T18:41:12 March 17th 2023, 10:03pm |
|
@FintelAlerts Insider Yat Sun Or reports selling 13,925 shares of $ENTA for a total cost of $618,960.24 https://t.co/UuZn8ztwuL March 17th 2023, 10:03pm |
|
@FlashAlert_me $ENTA [15s. delayed] filed SEC form 4: Sr. VP & CSO Or Yat Sun: Disposed 13,925 of Common Stock at average price $… https://t.co/VP1wrtyuUf March 17th 2023, 10:03pm |
|
@day_trading_de ENTA (ENANTA PHARMACEUTICALS INC) ? #Insider #stock alert! ? #Sale on 2023-03-15 - $ENTA ??: Or Yat Sun (Sr. VP & C… https://t.co/ZztBu0hm0u March 17th 2023, 10:03pm |
|
@insidertra $ENTA ENANTA PHARMACEUTICALS INC, Or Yat Sun, purchased shares valued at 194950 USD, date 2023-03-15, posted 2023-03-17T18:37:22 ? March 17th 2023, 10:03pm |
|
@insidertra $ENTA, ENANTA PHARMACEUTICALS INC, Or Yat Sun, sold shares valued at 618960 USD, date 2023-03-15, posted 2023-03-17T18:37:22 March 17th 2023, 10:03pm |
|
@mediasentiment $ENTA new alert at https://t.co/A7qrDashxw #stocks #daytrading #NYSE #NASDAQ #market 60 March 17th 2023, 8:03am |
|
@day_trading_de ENTA (ENANTA PHARMACEUTICALS INC) ? #Insider #stock alert! ? #Sale on 2023-03-13 - $ENTA ??: Luly Jay R. (President… https://t.co/Bd2BUP61UR March 14th 2023, 10:03pm |
|
@insidertra $ENTA, ENANTA PHARMACEUTICALS INC, Luly Jay R., sold shares valued at 1260628 USD, date 2023-03-13, posted 2023-03-14T18:26:03 March 14th 2023, 10:03pm |
|
@insidertra $ENTA ENANTA PHARMACEUTICALS INC, Luly Jay R., purchased shares valued at 390768 USD, date 2023-03-13, posted 2023-03-14T18:26:03 ? March 14th 2023, 10:03pm |
|
@FintelAlerts Insider Luly Jay R. reports selling 27,912 shares of $ENTA for a total cost of $1,260,628.34 https://t.co/Hhx3ehc37w March 14th 2023, 10:03pm |
 |
@astockwatch1 $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/0MtouAmnYR March 14th 2023, 10:03pm |
 |
@OzmosiHealth $ENTA Enanta Pharmaceuticals to present new data for EDP-235, its 3CL Protease Inhibitor, in development as an oral… https://t.co/P3rMqM66m8 March 14th 2023, 4:03pm |
 |
@MarcJacksonLA $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/6Xil4XvlJF March 14th 2023, 2:03pm |
 |
@Briefingcom $ENTA: Enanta Pharmaceuticals to present new data for eDP-235, its 3CL protease inhibitor, in development as an... https://t.co/d2SMCv58PP March 14th 2023, 1:03pm |
 |
@otcdynamics $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/AZQwNturQ8 March 14th 2023, 12:03pm |
|
@otcdynamics $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/SBMJVjKBoi March 14th 2023, 11:03am |
 |
@James__BondOO7 RT @stock_titan: $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-… March 14th 2023, 11:03am |
 |
@StockNewsBot2 $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/Fe1MfirzVZ March 14th 2023, 11:03am |
 |
@stock_titan $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/koLfJ5oAYq March 14th 2023, 11:03am |
 |
@WebChronicleTo1 $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/USOnsxkU08 March 14th 2023, 11:03am |
|
@Tickeron Does this make you nervous? $ENTA price may climb as it broke lower Bollinger Band. #EnantaPharmaceuticals… https://t.co/WyvpFOsHJs March 12th 2023, 12:03am |
|
@MarcJacksonLA $ENTA Enanta Pharmaceuticals Says Less Than 5% of Assets Held in Silicon Valley Bank Accounts https://t.co/tWXQR4qqag March 11th 2023, 5:03pm |
 |
@ChartMill $ENTA was analyzed by 16 analysts. The buy consensus is at 79%. So analysts seem to be mildly confident about $ ...… https://t.co/YygIorgttl March 11th 2023, 2:03pm |
 |
@signaljumper $ENTA ++upcoming data++ phase1 #chartcheck #signaljumper #followme support red targets green channel formi… https://t.co/IQ0e52c6ec March 11th 2023, 9:03am |
 |
@DewDiligence Scratch the above—I misread the 8-K filing. $ENTA's worst-case SVB exposure is ~$12M: https://t.co/0GOy7U9aVC March 11th 2023, 1:03am |
|
@DewDiligence $ENTA's maximum exposure to SVB is only about $2M: https://t.co/QiBbPOEajM March 11th 2023, 12:03am |
 |
@Ainvest_Wire Enanta Pharmaceuticals says less than 5% of assets held in Silicon Valley Bank accounts $SIVB $ENTA #Ainvest… https://t.co/52n7WAKcYY March 10th 2023, 10:03pm |
 |
@algobotnews Enanta says less than 5% of its cash, marketable securities held in SVB accounts $ENTA $SIVB March 10th 2023, 9:03pm |
 |
@investor_feed $ENTA 8-K Enanta Pharmaceuticals (10 Mar, 4:43pm) ? Regulation FD Disclosure https://t.co/ZWJ3qXpzH0 #ENTA… https://t.co/3XwBZ1VGQR March 10th 2023, 9:03pm |
|
@FintelAlerts $ENTA / Enanta Pharmaceuticals files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 2… https://t.co/PoLLbzJEkN March 10th 2023, 9:03pm |
|
@otcdynamics $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/GIUdfUuk3E March 8th 2023, 4:03pm |
 |
@CHItraders $ENTA Enanta Pharmaceuticals To Present New Data For EDP-235, Its 3CL Protease Inhibitor, In Development As An Oral… https://t.co/fvevlw1k7e March 8th 2023, 1:03pm |
 |
@BloombergFeed $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/dZFOnl6AYp March 8th 2023, 1:03pm |
|
@StockNewsBot2 $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/BBDaUY0g5i March 8th 2023, 1:03pm |
|
@stock_titan $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/AIUg4UPahJ March 8th 2023, 1:03pm |
|
@WebChronicleTo1 $ENTA Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral… https://t.co/UxsyvW9hZ0 March 8th 2023, 1:03pm |
|
@FlashAlert_me $ENTA [15s. delayed] filed form 8-K on March 07, 16:00:34 https://t.co/Ec9lXr43h4 March 7th 2023, 9:03pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2023. All rights reserved.